These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 25096555

  • 1. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.
    Biol Ther; 2014 Dec; 4(1-2):27-39. PubMed ID: 25096555
    [Abstract] [Full Text] [Related]

  • 2. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020 Dec; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
    Backeljauw P, Kanumakala S, Loche S, Schwab KO, Pfäffle RW, Höybye C, Lundberg E, Battelino T, Kriström B, Giemza T, Zouater H.
    Horm Res Paediatr; 2021 Dec; 94(3-4):133-143. PubMed ID: 34350858
    [Abstract] [Full Text] [Related]

  • 7. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
    Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J.
    Health Technol Assess; 2010 Sep; 14(42):1-209, iii-iv. PubMed ID: 20849734
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.
    Ross JL, Lee PA, Gut R, Germak J.
    Int J Pediatr Endocrinol; 2015 Sep; 2015(1):1. PubMed ID: 25904938
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data.
    Romer T, Zabransky M, Walczak M, Szalecki M, Balser S.
    Biol Ther; 2011 Sep; 1(1):5. PubMed ID: 24392295
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP, Walczak M, Birkholz-Walerzak D, Szalecki M, Nanu M, Woehling H, Schuck E.
    Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
    [Abstract] [Full Text] [Related]

  • 17. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, Berghout A.
    Horm Res; 2009 Mar; 72(6):359-69. PubMed ID: 19844125
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L, Liang Y, Wu W, Lin HH, Luo XP, Ying YQ.
    Growth Horm IGF Res; 2020 Mar; 53-54():101331. PubMed ID: 32777706
    [Abstract] [Full Text] [Related]

  • 19. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT, Elawwa A, Itani M, Jour C, De Sanctis V.
    Acta Biomed; 2019 Sep 23; 90(8-S):43-51. PubMed ID: 31544806
    [Abstract] [Full Text] [Related]

  • 20. Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.
    Flodmark CE, Lilja K, Woehling H, Järvholm K.
    Biol Ther; 2013 Sep 23; 3(1):35-43. PubMed ID: 24392303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.